title: Effects of intravitreal bevacizumab treatment on proliferative retinopathy in a patient with cerebroretinal vasculopathy.
authors.forename: Marcus
authors.initials: M
authors.lastname: Kernt
authors.forename: Andreas
authors.initials: A
authors.lastname: Gschwendtner
authors.forename: Aljoscha S
authors.initials: AS
authors.lastname: Neubauer
authors.forename: Martin
authors.initials: M
authors.lastname: Dichgans
authors.forename: Christos
authors.initials: C
authors.lastname: Haritoglou
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D012160:Retina / Q000473:pathology / Q000503:physiopathology; D012161:Retinal Artery / Q000187:drug effects / Q000503:physiopathology; D012164:Retinal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab